Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-04-02
2010-11-16
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07833736
ABSTRACT:
The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided.
REFERENCES:
patent: 5443962 (1995-08-01), Draetta et al.
patent: 6218136 (2001-04-01), Kumar et al.
patent: 2003/0129606 (2003-07-01), Davis et al.
patent: 2003/0143582 (2003-07-01), Reed et al.
patent: 2004/0038323 (2004-02-01), Zhan et al.
patent: 2004/0265938 (2004-12-01), Remacle et al.
patent: 2006/0019252 (2006-01-01), Nakamura et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 1564305 (2005-08-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Malusecka et al (Anticancer Research, 2001, 21:1015-1022).
Zoumpourlis et al (Oncogene, 2000, 19:4011-4021).
Petti et al., “Temporal quantification of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor,” OSI-930' Mol. Cancer Ther. 4(8): 1186-1197 (Aug. 2005) USA.
Palancade et al., “Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation,” Eur. J. Biochem 270: 3859-3870 (2003) Paris, France.
Raught et al., “Phosphorylation of eukaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases,” EMBO Journal 23: 1761-1769 (2004) USA.
Dai et al., “The kinase haspin is required for mitotic histone HE Thr3 phosphorylation and normal metaphase chromosome alignment,” Genes & Development 19: 472-488 (2005) USA.
Haack Herbert
Sullivan Laura
Cell Signaling Technology, Inc.
Goddard Laura B
Wilker Nancy Chiu
LandOfFree
Protein markers of responsiveness to type III receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein markers of responsiveness to type III receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein markers of responsiveness to type III receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251020